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Abstract 
Context: First or early second trimester pregnancy-associated plasma protein-A (PAPP-A) 
concentrations have previously been shown to be lower in women who subsequently develop 
gestational diabetes (GDM) and gestational hypertension. Objective: We therefore sought to 
investigate why circulating PAPP-A concentrations are related to the subsequent risk of GDM and 
gestational hypertension. Patients, Design and Setting: We measured serum PAPP-A 
concentrations around week 15 of pregnancy and related these to indices derived from week 28 oral 
glucose tolerance tests (OGTT) and blood pressures across pregnancy in the Cambridge Baby 
Growth Study cohort. Results: Increased PAPP-A concentrations were associated with reduced GDM 
risk (odds ratio 0.623 (0.453, 0.856), P=3.5 x 10-3, n=777) and reduced mean arterial blood pressures 
(β=-0.202– -0.177, P=1.7–6.9 x 10-3, n=347–355). They were also negatively associated with week 28 
fasting (β=-0.149, P=6.6 x 10-4, n=777) and 60 minute (β=-0.188, P=1.5 x 10-5, n=777) OGTT glucose 
concentrations. These associations were underpinned by the strong associations between increased 
week 15 PAPP-A concentrations and decreased week 28 insulin resistance (HOMA IR: β=-0.319, 
P=1.7 x 10-13, n=768), and increased insulin secretion relative to insulin sensitivity (insulin disposition 
index: β=0.202, P=6.5 x 10-6, n=731). Conclusions: These results suggest that links between PAPP-
A concentrations in early pregnancy and subsequent glucose concentrations and blood pressures 
may be mediated by changes in insulin sensitivity (and secretion). 
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Introduction 
Pregnancy associated plasma protein A (PAPP-A) is produced by the placenta in pregnancy and is 
one of only four placentally-derived proteins found in the maternal circulation in high concentrations. 
(1) It largely circulates as a heterotetramer consisting of two PAPP-A subunits covalently bound to 
two subunits of the preform of eosinophil major basic protein. (2) PAPP-A’s principal function as a 
metalloproteinase of the metzincin superfamily, appears to be the cleavage of circulating insulin-like 
growth factor binding protein 4 (IGFBP-4), although there are suggestions that PAPP-A may also be 
involved in the cleavage of IGFBP -2 (3) and -5. (4) It is only the uncomplexed, dimeric form of PAPP-
A, the proportion of which varies throughout pregnancy but is around 1 % of circulating 
concentrations, which displays this proteolytic activity. (5) Whichever binding protein uncomplexed 
PAPP-A cleaves it would appear to have a role in regulating IGF bioavailability in pregnancy. (6) This 
is important as the IGF axis plays a critical role in fetal growth, and placental growth and function 
during pregnancy. (7) 
 
Measurement of circulating PAPP-A concentrations is used, along with nuchal translucency scanning 
and free β-human chorionic gonadotrophin concentration measurement, in first trimester screening for 
fetal chromosomal abnormalities including Down Syndrome, Patau Syndrome and Edward Syndrome 
(trisomies 21, 13 and 18, respectively). In pregnancy circulating PAPP-A concentrations are also 
influenced by such factors as gestational age (increasing in a curvilinear fashion with gestational age), 
maternal weight (decreasing with increasing weight) and height (increased with increasing height), 
ethnicity (higher in women of Afro-Caribbean, East Asian and South Asian racial origin), method of 
conception (decreased in first trimester and raised in the third trimester with in vitro fertilisation), parity 
(decreased in parous women) and smoking status (decreased in smokers). (8) In addition they appear 
to be decreased by pre-existing type 1 and type 2 (8) diabetes. A number of studies have found 
associations between reduced circulating PAPP-A concentrations early in pregnancy and the 
subsequent development of gestational diabetes (GDM) (9-16), although these are not uniform 
occurrences. (17, 18) Where such associations have been found, studies have tended not to 
investigate mechanisms that may be underpinning these associations. Other studies have found 
associations between reduced circulating PAPP-A concentrations early in pregnancy and the 
development of gestational hypertension (13, 19) or pre-eclampsia later in pregnancy (20, 21), 
conditions that are commonly linked with GDM. As both GDM and gestational hypertension can 
impact upon the baby’s birth weight, early pregnancy circulating PAPP-A concentrations have been 
related to birth weight in several studies. (16, 18, 22-29) In this study we attempted to extend the 
relationships of early pregnancy PAPP-A concentrations with the adverse conditions of pregnancy to 
other markers of impaired glucose tolerance derived from the oral glucose tolerance test (OGTT) and 
high blood pressures. We hypothesised that the relationships were mediated by changes in IGF 
bioactivity. 
 
Research Design and Methods 
Cambridge Baby Growth Study 
The Cambridge Baby Growth Study (prospective and longitudinal) recruited mothers attending 
ultrasound clinics during early pregnancy at the Rosie Maternity Hospital, Cambridge, U.K., between 
2001 and the present. Blood samples were drawn at recruitment (and centrifuged, the serum 
separated and stored at -80 oC until analysis). There were two main phases of recruitment for the 
Cambridge Baby Growth Study, phase I running from 2001 until 2009, from which the samples used 
in this study were obtained. Blood samples were collected on average at week 15 of pregnancy at the 
booking clinic (n=821). Table 1 shows the clinical characteristics of the study participants who had 
blood samples taken. At 28 weeks of gestation, 1,074 of the mothers underwent a 75-g OGTT after 
an overnight fast. Venous blood was collected after fasting and at 60 min. after the glucose load for 
the measurement of plasma glucose concentrations (using a routine glucose oxidase–based method). 
Capillary whole blood glucose concentrations were measured at 0, 30, 60, 90 and 120 mins. using an 
Abbott Freestyle Mini (Abbott Diagnostics, Maidenhead, U.K.). Routine blood pressure measurements 
during three time points in pregnancy were documented from hospital notes. (30) The baby’s birth 
weights were recorded by hospital midwives and retrieved from the hospital notes. In this cohort, 
96.9 % of the offspring were of Caucasian ethnicity, 0.8 % were of mixed race, 0.6 % were black 
(African or Caribbean), 0.8 % were Oriental, and 0.9 % were Indo-Asian. 
 
Disease Diagnostic Thresholds 
The Cambridge Baby Growth Study participants were divided into cases and controls for GDM 
according to the International Association of Diabetes in Pregnancy Study Group criteria (31) using 
the OGTT fasting and 60 min. plasma glucose concentrations. Its prevalence in the Cambridge Baby 
Growth Study was 10.2 %. Evidence of gestational hypertension was sought from the hospital notes 
(defined using the inclusion of a diagnosis of pre-eclampsia, gestational hypertension or pregnancy-
induced hypertension). Alternatively the National Institute for Health and Care Excellence criteria for 
defining gestational hypertension (blood pressure measurements in the second half of pregnancy 
>= 140 mmHg systolic or 90 mmHg diastolic blood pressure in women without chronic hypertension) 
(32) were used, with the exception that for our study evidence of gestational hypertension was 
accepted if the blood pressure cut offs were exceeded at one reading rather than at least two. Its 
prevalence in the Cambridge Baby Growth Study was 6.1 %. (30) 
 
Cohort Subgroups 
The 821 serum samples collected early in the second trimester of pregnancy were ordered according 
to their PAPP-A concentrations. The 48 samples with the lowest PAPP-A concentrations formed the 
“low PAPP-A” group and the 48 samples with the highest PAPP-A concentrations formed the “high 
PAPP-A” group. Bioactive IGF was estimated in these subgroups. 
 
Ethical Approval 
The Cambridge Baby Growth Study was approved by the local ethics committee, Addenbrooke’s 
Hospital, Cambridge, U.K. Written informed consent was obtained from all the mothers who took part 
in this study. 
 
Circulating Hormone Concentration Measurements 
PAPP-A was measured by time-resolve fluoroimmunoassay (autoDELFIA, Perkin Elmer Ltd., Seer 
Green, U.K.). The minimum detection limit of this assay was 22.5 mg/L (5 mU/L). The intra-assay 
coefficient of variation (CV) was less than 8 % and the inter-assay CV was less than 10 % throughout. 
Insulin was measured by enzyme-linked immunosorbent assay using a commercial kit (DSL, London, 
U.K.). Sensitivity was 0.26 mU/L (1.6 pmol/L). Intra-assay CVs were 4.4 and 5.1 % at 10.4 mU/L 
(62 pmol/L) and 35.9 mU/L (215 pmol/L), and equivalent inter-assay CVs were 8.7 and 2.9 %; this 
assay has no cross-reactivity with proinsulin at levels up to 9.1 µg/L (1,000 pmol/L). Bioactive IGF is a 
cell-based measurement, which assesses the ability of serum IGF-I and IGF-II to phosphorylate the 
IGF-I receptor (IGF1R) in vitro, using human embryonic cells transfected with cDNA of the human 
IGF1R gene (33). The serum signal is compared with a serial IGF-I dilution and expressed in µg/L. 
The detection of phosphorylated IGF1R in crude cell lysates was performed using a commercial kit 
(catalogue #DYC 1770E) from R & D Systems (Abingdon, U.K.). Sensitivity was < 0.08 µg/L. The 
intra-assay CV averages 6 % for the signals and 12 % for the corresponding concentrations; the long-
term inter-assay CV is 20 %. 
 
Calculations 
Mean arterial blood pressure was calculated as the sum of the systolic and twice the diastolic blood 
pressures, all divided by three. Insulin sensitivity was estimated using the Homeostasis Model 
Assessment (HOMA), calculated using the week 28 circulating glucose and insulin concentrations and 
the online HOMA calculator (available at https://www.dtu.ox.ac.uk/homacalculator/). Insulin secretion 
was assessed in terms of the insulinogenic index, calculated as (insulin 60 min. − insulin 0 min.)/ 
(glucose 60 min. − glucose 0 min.). The insulin secretion for the given insulin sensitivity was assessed 
in terms of the insulin disposition index, calculated as the insulinogenic index divided by the reciprocal 
of the fasting insulin concentration. The areas under the whole capillary blood glucose curve (AUC) of 
the OGTT were calculated using the trapezoid rule. Those under receiver operating characteristic 
(ROC) curves were calculated using the “lroc” function of Stata. The body mass index (BMI) was 
calculated as the pre-pregnancy weight (kg) divided by the height (m) squared. A BMI < 25 kg/m2 was 
considered lean, 25-30 was considered overweight and > 30 was considered obese. 
 
Statistical Analysis 
Associations were tested by linear regression (for continuous dependent variables) or logistic 
regression (for binary dependent variables). All the analyses involving PAPP-A were adjusted for the 
number of weeks of pregnancy when the blood samples was taken. Log-transformed data were 
analysed in this study when required to normalise the distribution of the residuals, as required for the 
linear regression. ROC curve equality was tested using Stata’s “roccomp” function. Data are mean 
(95 % confidence interval) unless stated otherwise. P < 0.05 was considered statistically significant 
throughout. Statistical analyses were performed using Stata 13 (StataCorp LP, College Station, 
Texas, U.S.A.). 
 
Results 
Association with GDM and Gestational Hypertension 
Maternal serum PAPP-A concentrations at week 15 were significantly associated with a protective 
effect on the development of GDM by week 28 of pregnancy (odds ratio (OR) 0.623 (0.453, 0.856), 
p=3.5x10-3, McFadden’s pseudo r2=1.7%, n=777). The ROC curve AUC was 0.592. Adding PAPP-A 
to an established model for predicting GDM containing BMI and age did not improve the AUCs (going 
to 0.639 from 0.647 without PAPP-A; n=581; p=0.3; Fig. 1). After adjusting for pre-pregnancy BMI the 
statistical significance of the association between GDM and PAPP-A concentrations was lost (p=0.5). 
Analysing associations in lean (OR 1.164 (0.677, 1.999), p=0.6, n=434 of which 24 developed GDM), 
overweight (OR 0.629 (0.322, 1.228), p=0.18, n=140 of which 20 developed GDM) and obese (OR 
0.545 (0.370, 0.804), p=2.2x10-3, n=241 of which 11 developed GDM) women separately, the 
significant relationship was only seen in obese women. Adjusting the model for fetal sex did not alter 
the significance of the association between GDM and PAPP-A concentrations (OR 0.617 (0.448, 
0.850), p=3.1x10-3, pseudo r2=1.8%, n=775), although the relationship was stronger in male (OR 
0.575 (0.381, 0.867), p=8.2x10-3, pseudo r2=2.8%, n=407) than female (OR 0.670 (0.399, 1.123), 
p=0.1, pseudo r2=1.8%, n=368) fetus pregnancies. Associations of maternal serum PAPP-A 
concentrations at week 15 with the subsequent development of gestational hypertension did not quite 
reach statistical significance in the number of participants studied (odds ratio 0.613 (0.365, 1.030), 
p=0.065, McFadden’s pseudo r2=2.1 %, n=361). 
 Association with Maternal Late Pregnancy Glucose Concentrations and Indices of Insulin Secretion 
and Sensitivity in the OGTT 
Maternal serum PAPP-A concentrations at week 15 were significantly negatively associated with 
week 28 fasting plasma glucose concentrations (standardised β=-0.149, r2=1.2 %, p=6.6x10-4, n=777) 
and areas under the capillary blood glucose curve (standardised β=-0.144, r2=1.1 %, p=3.2x10-3, 
n=610) (Fig. 2a and 2b). It was also negatively associated with week 28 HOMA IR (standardised 
β=-0.319, r2=6.6 %, p=1.7x10-13, n=768), an association which had the largest effect size (Fig. 2c). 
This relationship upheld when the model was adjusted for fetal sex (standardised β=-0.324, r2=6.8%, 
p=8.2x10-14, n=766), and when analysing male fetus (standardised β=-0.377, r2=9.0%, p=4.5x10-10, 
n=402) and female fetus (standardised β=-0.268, r2=4.5%, p=1.8x10-5, n=364) pregnancies 
separately. Additional negative associations were found between PAPP-A concentrations and plasma 
glucose concentrations 60 minutes after the 75 g glucose load and the insulin disposition index (Table 
2). 
  
Association with Mean Arterial Blood Pressure in Pregnancy 
Maternal serum PAPP-A concentrations at week 15 were significantly negatively associated with 
maternal mean arterial blood pressure at the readings taken around weeks 12, 31 and 37 of 
pregnancy (Table 3). Maternal mean arterial blood pressures were also significantly negatively 
associated with week 28 HOMA IR at weeks 12 (standardised β-coefficient=-0.219, p=1.9x10-6, 
n=465), 31 (standardised β-coefficient=-0.264, p=7.0x10-9, n=468) and 37 (standardised β-
coefficient=-0.318, p=5.7x10-12, n=458). 
 
Association of Maternal PAPP-A Status with Circulating IGF Bioactivity 
Those women with the highest serum PAPP-A concentrations had lower pre-pregnancy BMIs, at 
week 15 were more insulin sensitive at week 28 than those with the lowest PAPP-A concentrations, 
had slightly lower fasting glucose concentrations at week 28 and lower mean arterial blood pressures 
in the second half of pregnancy (Table 4). There was no detectable difference in circulating bioactive 
IGF activity however. 
 
Association with Baby’s Birth Weight 
Maternal serum PAPP-A concentrations at week 15 were not significantly associated with either the 
baby’s unadjusted birth weight (standardised β=-0.005, p=0.9, n=772) or with birth weight adjusted for 
gestational age at birth, sex and parity (standardised β=0.009, p=0.8, n=768). However there was a 
significant positive association when adjustment was made for gestational age at birth, sex, maternal 
weight prior to pregnancy, parity, smoking and gestational age when the blood samples were taken 
(standardised β=0.112, p=8.4x10-3, n=642). 
 
Discussion 
In this study we have confirmed negative associations between early pregnancy serum PAPP-A 
concentrations and subsequent development of GDM and high blood glucose concentrations. Our 
ROC curve analyses suggest that such PAPP-A measurements do not offer an advantage over 
established risk factors for the prediction of GDM development however. Sub-group analysis revealed 
that the negative association between GDM and PAPP-A was only detectable in obese women and 
was stronger in male fetus pregnancies. It is difficult to know if this reflects a physiological relationship 
in obese women/male fetus pregnancies or just a lack of statistical power in the other groups. The 
negative association between PAPP-A concentrations and gestational hypertension, as observed in 
other studies (13, 19), almost reached statistical significance in our study (presumably the reason that 
it did not was due to insufficient statistical power in the lower number of pregnancies studied). 
Negative associations with mean arterial blood pressures were, however, observed. Uniquely this 
study showed that the strongest association between early pregnancy PAPP-A concentrations and an 
index from the week 28 OGTT was with HOMA IR, suggesting that the principal reason PAPP-A is 
related to the future development of GDM and high blood pressures is via regulation of insulin 
sensitivities (high circulating glucose concentrations and blood pressures both being related to 
reduced insulin sensitivity). As GDM is related to relative reductions in both insulin secretion and 
insulin sensitivity, it is also not surprising that another relationship was observed between the early 
pregnancy PAPP-A concentrations and the insulin disposition index, although the strongest 
relationship by far remained the one with insulin sensitivity. 
 
The role of circulating PAPP-A in pregnancy appears to be cleavage of certain IGFBPs. Given that 
circulating free (35) as well as total (36) IGF-I appears to influence insulin sensitivity, we hypothesised 
that the strong associations observed with GDM, high blood pressures and insulin sensitivity are 
underpinned by PAPP-A regulating IGF bioavailability in pregnancy which in turn regulates insulin 
sensitivity and ultimately contributes to protection against or the development of certain adverse 
conditions of pregnancy. However we could not detect a difference in IGF bioactivity between women 
with some of the highest week 15 circulating PAPP-A concentrations and women with some of the 
lowest, despite having large differences in week 15 PAPP-A concentrations and week 28 insulin 
sensitivities. One possible explanation of this is the lack of statistical power available to us in trying to 
detect a difference in IGF bioactivity in only 96 samples. Alternatively PAPP-A may affect localised 
rather than circulating IGF-I and –II concentrations. (2) The physiology of the IGF axes and insulin 
sensitivity is complicated due to the presence of IGF binding proteins and differences between 
localised and circulating IGF concentrations. One previous pregnancy study failed to find a 
relationship around week 28 between either serum total IGF-I or –II concentrations and insulin 
sensitivity (37), whilst another more recent study found a negative association between week 28 
serum total IGF-I concentrations and insulin sensitivity (38). A further study found higher weeks 24-28 
total IGF-I concentrations in women with GDM (39), possibly resulting from these women having 
higher placental growth hormone drive which could lead to reduced insulin sensitivity despite higher 
circulating IGF-I concentrations (40). 
 
A number of other studies (16, 22-28) have found positive associations between early PAPP-A and 
the baby’s birth weight, although this finding is not universal. (18, 29) Indeed we failed to find an 
association when analysing raw or minimally adjusted data. However close inspection of the other 
studies reveals that finding such an association depends on whether PAPP-A levels were analysed in 
terms of multiples of the median or just unadjusted concentrations. When we adjusted our PAPP-A 
concentrations for as many of the factors as that are used in the calculation of multiples of the median 
as we had available to us, the association with baby birth weights emerged. This was not surprising 
given that in our cohort the week 28 mother’s insulin sensitivity and glucose concentrations, both of 
which were associated with week 15 PAPP-A concentrations, were related to the baby’s birth weight. 
 
Although reasonably sized, this study has a number of limitations. Firstly the number of blood 
pressure readings available to us was relatively modest and we could not confirm the association 
between early pregnancy circulating PAPP-A concentrations and the development of gestational 
hypertension. The fact that circulating PAPP-A concentrations had significant associations with blood 
pressures throughout pregnancy suggests that the study was underpowered to find such an 
association with gestational hypertension (dichotomous variable analyses having less statistical 
power than analyses using continuous variables). However the association with blood pressures 
tempers this limitation somewhat, and there was sufficient power to detect an association between 
gestational hypertension and insulin sensitivity. Secondly the PAPP-A and bioactive IGF 
concentration measurements were not done in the same sample as those used for the insulin and 
glucose concentrations. We do not know if the week 28 PAPP-A and bioactive IGF concentrations 
track those at week 15. However the study was designed to enhance previous findings showing first 
trimester PAPP-A concentrations are negatively related to the subsequent development of GDM, 
which has been achieved. Given the strength of the various associations it is possible that the week 
15 and 28 results would be related albeit probably imperfectly (8). The final limitation is that the study 
was designed to replicate first trimester findings and technically the stage of pregnancy when the 
blood samples were adjusted to, at week 15, was in the second trimester. Although PAPP-A values 
would probably have been higher at week 15 than earlier in pregnancy (8) the factors that affect 
circulating PAPP-A concentrations in pregnancy, apart from gestational age and maternal weight and 
height, tend to be fixed rather than fluid (8) so the association trends are unlikely to have been 
affected. 
 
In summary we confirmed associations between circulating PAPP-A concentrations in week 15 of 
pregnancy and the future development of GDM and high blood pressure. Underpinning these 
associations was an even stronger association with insulin sensitivity, which may relate to the 
cleavage of IGFBPs by PAPP-A leading to increases in bioactive IGF which regulates insulin 
sensitivity, at least outside pregnancy (35, 36). Further studies on the effect of IGFs on insulin 
sensitivity in pregnancy would therefore appear warranted. 
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Table 1 Clinical characteristics of the Cambridge Baby Growth Study participants who had week 15 
serum PAPP-A concentrations measured. 
 
Demographic  
N 821 
Maternal age at birth of baby (years) 33.2 
(32.9, 33.5) 
(n=689) 
Parity 1.7 
(1.6, 1.8) 
(n=779) 
Pre-pregnancy BMI (kg/m2) 24.1 
(23.9, 24.5) 
(n=643) 
Unadjusted birth weight of baby (kg) 3.498 
(3.462, 3.535) 
(n=779) 
Percentage giving birth to males (%) 52.6 
Gestational age of offspring at delivery (decimal weeks) 39.9 
(39.8, 40.0) 
(n=782) 
Percentage that smoked at any point during pregnancy (%) 4.1 
Percentage that developed GDM (%) 8.9 
Percentage that developed gestational hypertension (%) 6.0 
Data are mean (95 % confidence intervals) or percentages.   
Table 2 Association between maternal PAPP-A concentrations at week 15 (15.0 (14.8, 15.1) weeks) 
of pregnancy and week 28 OGTT indices of maternal glucose tolerance and insulin resistance and 
secretion. 
Index Standardised 
Coefficient (β) 
p-value r2 (%) n 
Plasma glucose concentration 60 min. after a 
75 g glucose load 
-0.188 1.5 x 10-5 2.4 777 
HOMA S 0.319 1.8 x 10-13 6.6 768 
Insulinogenic index -0.024 0.6 0 731 
Insulin disposition index 0.202 6.5 x 10-6 2.6 731 
  
 
  
Table 3 Association between maternal PAPP-A concentrations around week 15 of pregnancy and 
mean arterial blood pressure across pregnancy. 
Pregnancy Stage (weeks) Standardised Coefficient (β) p-value r2 (%) n 
11.8 (11.5, 12.0) -0.187 4.1 x 10-3 1.6 352 
31.4 (31.3, 31.5) -0.202 1.7 x 10-3 2.3 355 
37.0 (36.9, 37.0) -0.177 6.9 x 10-3 2.5 347 
 
  
Table 4 Comparison of the groups selected as having the highest and lowest unadjusted week 15 
serum PAPP-A concentrations in terms of clinical characteristics, week 28 OGTT indices of maternal 
glucose tolerance, insulin secretion and insulin sensitivity plus blood pressures. 
Index Pregnancy 
Stage 
(weeks) 
Lowest 
PAPP-A 
concentrations 
Highest 
PAPP-A 
concentrations 
Standardised 
Coefficient (β) 
p-
value 
Maternal Age 
(decimal years) 
Birth of baby 32.7 
(31.4, 34.1) 
(n=48) 
33.0 
(31.6, 34.3) 
(n=48) 
0.027 0.8 
Parity Throughout 1.8 
(1.5, 2.1) 
(n=48) 
1.6 
(1.3, 1.8) 
(n=48) 
-0.130 0.2 
Pre-pregnancy BMI 
(kg/m2) 
0 27.1 
(25.4, 28.7) 
(n=39) 
22.0 
(20.2, 23.8) 
(n=33) 
-0.442 1.0 x 
10-4 
Percentage giving 
birth to males (%) 
Birth of baby 54.5 51.1 N/A 0.7 
Percentage 
smoking (%) 
At any time 
during 
pregnancy 
8.9 4.5 N/A 0.4 
Percentage who 
develop GDM (%) 
> 20 16.7 4.2 N/A 0.09 
PAPP-A (mU/L) 15 1096 
(906, 1326) 
(n=48) 
18126 
(14983, 21929) 
(n=48) 
0.836 2.0 x 
10-31 
Bioactive IGF 
(IGF-IR Activation) 
(µg/L) 
15 2.57 
(2.32, 2.81) 
(n=44) 
2.68 
(2.44, 2.92) 
(n=46) 
0.070 0.5 
Fasting plasma 
glucose (mg/dL) 
28 79 
(77, 83) 
(n=48) 
76 
(74, 79) 
(n=48) 
-0.234 0.02 
Plasma glucose 60 
min. after a 75 g 
glucose load 
(mg/dL) 
28 132 
(123, 141) 
(n=48) 
124 
(115, 133) 
(n=48) 
-0.103 0.3 
Area under the 
curve of capillary 
whole blood 
glucose 
concentrations 
(g.min/dL) 
28 15.77 
(15.03, 16.49) 
(n=48) 
15.32 
(14.53, 16.09) 
(n=48) 
-0.100 0.4 
Insulinogenic index 
(Δins60/Δgluc60) 
28 148 
(122, 179) 
(n=48) 
144 
(118, 174) 
(n=48) 
-0.024 0.8 
Insulin disposition 
index (L/mmol) 
28 13135  
(10518, 16403) 
(n=48) 
17456 
(13978, 21798) 
(n=48) 
0.188 0.08 
HOMA IR  28  1.14  
(1.00, 1.30)  
(n=48) 
0.83  
(0.73, 0.99) 
(n=47) 
-0.331 1.0 x 
10-3 
Mean arterial blood 
pressure (mmHg) 
12 84 (78, 90) 
(n=16) 
79 (75, 84) 
(n=26) 
-0.214 0.4 
31 89 (85, 94) 
(n=16) 
78 (75, 82) 
(n=24) 
-0.522 5.9 x 
10-4 
37 91 (86, 96) 
(n=16) 
83 (79, 87) 
(n=24) 
-0.398 0.01 
Data are mean (95 % confidence intervals). Δins60 is the change in plasma insulin concentrations over 
the first hour of the OGTT. Similarly Δgluc60 is the change in plasma glucose concentrations over the 
first hour of the OGTT. N/A = not applicable.  
Figure Legends 
 
Figure 1 ROC curves for the prediction of GDM development based on: (1) week 15 serum PAPP-A 
concentrations (AUC=0.592 + 0.041), (2) maternal BMI before pregnancy and age (AUC=0.647 + 
0.042), and (3) a combination of (1) and (2) (AUC=0.639 + 0.041). N=581 per model, AUC data are 
mean + SEM. 
 
Figure 2 Scatter diagrams that illustrate the association between week 15 PAPP-A concentrations 
and week 28 (a) fasting plasma glucose concentrations, (b) areas under the capillary glucose curve 
from the OGTT and (c) insulin resistance (HOMA IR). Also shown are the regression lines and their 
95 % confidence intervals. All PAPP-A concentrations are natural log-transformed throughout. 
 
